Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain

Max Schlueter,1 Elaine Finn,1 Silvia Díaz,2 Tatiana Dilla,2 José Inciarte-Mundo,3 Walid Fakhouri41IQVIA, Real World Evidence, London N1 9JY, UK; 2Lilly Spain, Health Outcomes & RWE, Alcobendas 28108, Spain; 3Lilly Spain, Medical, Alcobendas 28108, Spain; 4Lilly, Global...

Full description

Bibliographic Details
Main Authors: Schlueter M, Finn E, Díaz S, Dilla T, Inciarte-Mundo J, Fakhouri W
Format: Article
Language:English
Published: Dove Medical Press 2019-06-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
baricitinib
cost-effectiveness
JAK inhibitor
rheumatoid arthritis
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-baricitinib-versus-adalimumab-for-the-t-peer-reviewed-article-CEOR

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-baricitinib-versus-adalimumab-for-the-t-peer-reviewed-article-CEOR

Similar Items